成人国产精品一级毛片视频,毛片三级在线观看,中国黄色在线观看,婷婷久久综合九色综合九七,久久久免费视频观看,国产99在线播放,日本成人福利

產品分類導航
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes

Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes

更新時間:2025-06-20

價格:  元/個
CAS號: 2023788-19-2
藥典: 中國藥典,企業(yè)標準
級別: injection
立即詢盤
收藏
產品詳情
產品關鍵詞: Dual-Action Agonist,Type 2 Diabetes Treatment,Weight Management,Once-Weekly Dosing,GIP/GLP-1 Receptor Activation
是否為生產商:
產品包裝規(guī)格: 5mg/Ampoule 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 30mg/Ampoule 10Ampoules/Box
主要銷售市場: 中國,北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產品描述:






Mechanism of Action(作用機理)

Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:

  1. GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.
  2. GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.
  3. Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.

Applications(應用)

  1. Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  2. Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.
  3. Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).

Dosage Instructions(用法用量)

  1. Initial Dose: The recommended starting dose is 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.
  3. Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage(保存)

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.


上海浦津林州制藥有限公司
注冊資本
聯(lián)系人
聯(lián)系電話
查看聯(lián)系方式
快速詢盤
詢盤主題
請輸入詢盤主題
詢盤信息
請輸入詢盤信息
滑動驗證
請完成滑塊驗證
快速發(fā)送詢盤
CPHI制藥在線為您找到Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 價格、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 詳細參數(shù)、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 相關產品、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 供應商等信息,想了解當前Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 最新報價,請聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國際展覽有限公司版權所有(保留一切權利) 滬ICP備05034851號-57
三都| 揭西县| 澎湖县| 景东| 神农架林区| 朝阳区| 石楼县| 福海县| 万山特区| 咸宁市| 茌平县| 罗山县| 延川县| 洛川县| 合作市| 白水县| 砚山县| 广丰县| 定西市| 鲁甸县| 集安市| 汶川县| 霍山县| 横山县| 灌云县| 河池市| 图木舒克市| 武川县| 苗栗县| 溆浦县| 永安市| 武山县| 依安县| 东阿县| 辽阳市| 霍州市| 广东省| 湘潭市| 孟州市| 陆良县| 北票市|